NEW YORK (GenomeWeb) – Belgian biopharmaceutical developer UCB announced today that it has acquired Durham, North Carolina-based Element Genomics for $30 million, which will include upfront and short-term success-based milestone payments.

A biotech spinout from Duke University, Element Genomics has developed several technologies to further understand genome structure and functions, such as CRISPR editing technology for genomic and epigenetic regulatory region analysis and modulation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.